INOVOTION has been awarded an ambitious project for automating its revolutionary Drug Discovery in vivo efficacy and toxicity testing technology. The underlying technology is already a game changer for developing new anticancer drugs: in vivo efficacy and toxicity data in 1 month, x5 affordable, x1000 sensitivity, x2 reliability, no animal testing, and it’s as predictive as other more classical models.
The consortium integrates Alprobotic’s expertise in robotics, the TIMC lab at University Grenoble Alpes (UGA) with expertise with in vivo imaging, INRIA’s expertise in Automated Learning, and the Hospices Civils de Lyon (HCL).
The speed and affordability of the INOVOTION approach also opens new perspectives for a novel Personalized Medicine approach: test patient biopsies with available treatments to identify the best one for each specific cancer. The HCL will carry out a clinical study within the project to validate this new application on two patient cohorts.
INOVOLINE leads the way to faster discovery of new cancer cures, and vastly improved patient care. This will be a world first for automatic in vivo testing.